目的 制备孟鲁司特钠口腔崩解片,进行比格犬体内生物等效性研究。方法 粉末直接压片法制备口腔崩解片,通过正交试验结果确定最优处方。采用HPLC-荧光检测法测定比格犬体内血药浓度。结果 口腔崩解片的优化处方为孟鲁司特钠10.4 g,微晶纤维素60 g,交联聚维酮30 g,甘露醇15 g,硬脂酸镁2 g,微粉硅胶1 g,阿司帕坦1 g,香精0.6 g,制成1 000片。结论 优化处方制备的口腔崩解片崩解迅速,相对生物利用度为90.7%。
Abstract
OBJECTIVE To prepare montelukast sodium orally disintegrating tablets and investigate the bioequivalence in Beagle dogs.METHODS The orally disintegrating tablets were prepared by direct compression method,and the optimal formulation was screened by orthogonal test.HPLC-fluorescence method was developed for determination of montelukast sodium plasma concentration in Beagle dogs.RESULTS The optimized formulation(1 000 tablets) was montelukast sodium 10.4 g, microcrystalline cellulose 60 g, cross linked povidone 30 g, mannitol 15 g, magnesium stearate 2 g, aerosil 1 g, aspartame 1 g, flavor 0.6 g.CONCLUSION Montelukast sodium orally disintegrating tablets made of the optimized formulation could disintegrate rapidly. Relatively bioavailability of montelukast sodium orally disintegrating tablets is 90.7%.
关键词
孟鲁司特钠 /
口腔崩解片 /
正交试验 /
生物等效性
{{custom_keyword}} /
Key words
montelukast sodium /
orally disintegrating tablet /
orthogonal test /
bioequivalence
{{custom_keyword}} /
中图分类号：
R944
R969.1
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] LIU F,ZHONG L Q. Study on the pharmacological activities and clinical application for montelukast sodium[J]. Chin J Clin Rational Drug Use(临床合理用药),2017,10(4C):83-84.
[2] LIU Y Z,JIN N,WANG H B. Analysis of therapeutic effect of montelukast sodium in treatment of asthma-chronic obstructive pulmonary disease[J]. J Clin Pulmon Med(临床肺科杂志),2017,22(7):1293-1296.
[3] HAO M,SONG W,LU L. The influence of montelukast on the balance of Th17/Treg and lung function of children with bronchial asthma[J]. Contemp Med(当代医学),2017,23(21):11-14.
[4] LIU D X,LI Y Q. Montelukast sodium combined with budesonide in the treatment of children with bronchiolitis and its impact on inflammatory factor[J]. J Pediatr Pharm(儿科药学杂志),2017,23(6):27-30.
[5] BADGUJAR B P, MUNDADA A S. The technologies used for developing orally disintegrating tablets: a review[J]. Acta Pharm, 2011,61(2):117-139.
[6] BI Y J,BAI F Z,GUO Y M. Domestic research progress on the bioequivalence of orally disintegrating tablets[J]. Chin J Biochem Pharm(中国生化药物杂志),2016,36(10):161-164.
[7] Ch.P(2015)Vol Ⅳ (中国药典2015年版.四部)[S].2015:118-119.
[8] GOHEL M, PATEL M, AMIN A, et al. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique[J]. Pharm Sci Tech,2004,5(3):1-6.
[9] CHEN L,ZHU Z J. Study on the disintegration test method for oral disintegrated tablet[J]. Chin J Hosp Pharm(中国医院药学杂志),2008,28(7):540-543.
[10] RAWAS-QALAJI M M, SIMONS F E, SIMONS K J. Fast-disintegrating sublingual tablets: effect of epinephrine load on tablet characteristics[J]. AAPS Pharm Sci Tech,2006,7(2):E1-E7.
[11] Ch.P(2015)Vol Ⅳ(中国药典2015年版.四部) [S].2015:120.
[12] LIN L,MA Z Y,QIAO Y, et al. Bioequivalence of montelukast dispersible tablets in healthy volunteers[J]. Pharm J Chin PLA(解放军药学学报),2011,27(4):334-336.
[13] GUO S R. Preliminary estimation of domestic PVPP as a tablet disintegrant[J]. Chin Pharm J(中国药学杂志),1999,34(6):384-386.
[14] GAO C H,ZHOU Y G,LI H B. Selection and combination of disintegrating agents for azithromycin dispersible tablets[J]. Chin J Pharm(中国医药工业杂志),2001,32(12):542-543.
[15] CUI F D. Pharmaceutics(药剂学)[M]. 7th ed.Beijing: People′s Medical Publishing House,2011:231.
[16] HAN L,ZHANG D K,QIN C F, et al. The determination of micromeritics parameters of dispersible tablet′s common excipients and the effects of SiO2 on TCM dispersible tablet′s disintegrating properties[J]. Chin J Hosp Pharm(中国医院药学杂志),2013, 33 (11):844-849.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家科技重大专项资助(2014ZX09507001)
{{custom_fund}}
PDF(1219 KB)
